Haoyu Sun1, Jiaxi Song1, Chenchun Weng1, Jing Xu2, Mei Huang3, Qiang Huang3, Rui Sun1, Weihua Xiao1, Cheng Sun1. 1. Institute of Immunology, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui, China. 2. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. 3. Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China.
Abstract
BACKGROUND AND AIM: The macrophage receptor with collagenous structure (MARCO) belongs to the scavenger receptor family; however, few studies have assessed their potentials in modulating inflammatory signaling other than the typical function of pattern recognition and phagocytic clearance. Interestingly, RNA-Seq analyses of hepatocellular carcinoma (HCC) have identified MARCO as one of the top 30 differentially expressed genes between cancerous and adjacent noncancerous tissues. However, no research has been performed to study MARCO in liver cancer. METHODS: MARCO protein expression was evaluated by immunostaining liver tissue specimens collected from 88 HCC patients, 10 liver cirrhosis patients, 6 metastatic patients, and 5 healthy controls. All sections were reviewed by blinded observers followed by the interpretation of integral optical density per area as a measure of protein intensity. RESULTS: We observed significantly decreased expression of MARCO in intratumoral tissues of HCC compared with expression in peritumoral tissues. The expression of MARCO declined progressively as the disease condition was aggravated, with the highest expression found in healthy controls and the lowest found in patients with HCC metastasis. Furthermore, MARCO expression decreased along with tumor progression. MARCO+ cells co-localized with CD68+ cells, indicating predominant expression on macrophages. The overall survival rate was significantly increased in patients with high intratumoral MARCO expression compared with that of patients with low intratumoral MARCO expression. CONCLUSIONS: Our study is the first to demonstrate an association between MARCO expression and the progression and prognosis of HCC.
BACKGROUND AND AIM: The macrophage receptor with collagenous structure (MARCO) belongs to the scavenger receptor family; however, few studies have assessed their potentials in modulating inflammatory signaling other than the typical function of pattern recognition and phagocytic clearance. Interestingly, RNA-Seq analyses of hepatocellular carcinoma (HCC) have identified MARCO as one of the top 30 differentially expressed genes between cancerous and adjacent noncancerous tissues. However, no research has been performed to study MARCO in liver cancer. METHODS:MARCO protein expression was evaluated by immunostaining liver tissue specimens collected from 88 HCC patients, 10 liver cirrhosispatients, 6 metastatic patients, and 5 healthy controls. All sections were reviewed by blinded observers followed by the interpretation of integral optical density per area as a measure of protein intensity. RESULTS: We observed significantly decreased expression of MARCO in intratumoral tissues of HCC compared with expression in peritumoral tissues. The expression of MARCO declined progressively as the disease condition was aggravated, with the highest expression found in healthy controls and the lowest found in patients with HCC metastasis. Furthermore, MARCO expression decreased along with tumor progression. MARCO+ cells co-localized with CD68+ cells, indicating predominant expression on macrophages. The overall survival rate was significantly increased in patients with high intratumoral MARCO expression compared with that of patients with low intratumoral MARCO expression. CONCLUSIONS: Our study is the first to demonstrate an association between MARCO expression and the progression and prognosis of HCC.
Authors: Stijn J H Waaijer; Frans V Suurs; Cheei-Sing Hau; Kim Vrijland; Karin E de Visser; Derk Jan A de Groot; Elisabeth G E de Vries; Marjolijn N Lub-de Hooge; Carolina P Schröder Journal: Front Oncol Date: 2021-12-16 Impact factor: 6.244
Authors: Sebastian Lundgren; Emelie Karnevi; Jacob Elebro; Björn Nodin; Mikael C I Karlsson; Jakob Eberhard; Karin Leandersson; Karin Jirström Journal: J Transl Med Date: 2017-07-03 Impact factor: 5.531
Authors: Rency S Varghese; Yuan Zhou; Megan Barefoot; Yifan Chen; Cristina Di Poto; Abdalla Kara Balla; Everett Oliver; Zaki A Sherif; Deepak Kumar; Alexander H Kroemer; Mahlet G Tadesse; Habtom W Ressom Journal: BMC Med Genomics Date: 2020-03-30 Impact factor: 3.063
Authors: Martin Jeremiasen; David Borg; Charlotta Hedner; Maria Svensson; Björn Nodin; Karin Leandersson; Jan Johansson; Karin Jirström Journal: Front Oncol Date: 2020-10-23 Impact factor: 6.244